Biophysics of Parkinson's disease: Structure and aggregation of α-synuclein

Current Protein and Peptide Science

Volumn 10, Issue 5, 2009, Pages 483-499

  Uversky, Vladimir N ^a,b   Eliezer, David ^c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE FOR BIOLOGICAL INSTRUMENTATION   (Russian Federation)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

synuclein; Aggregation; Amyloid; Fibril; Intrinsically disordered protein; Neurodegeneration; NMR; Partially folded intermediate; Synucleinopathies

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; ANION; BAICALEIN; BETA SYNUCLEIN; GAMMA SYNUCLEIN; HEAVY METAL; HERBICIDE; LEPROSTATIC AGENT; ORGANIC SOLVENT; PESTICIDE; POLYANION; POLYCATION; RIFAMPICIN; SODIUM CHLORIDE;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYOTROPHIC LATERAL SCLEROSIS; BIOPHYSICS; DIFFUSE LEWY BODY DISEASE; DOPAMINERGIC NERVE CELL; DOWN SYNDROME; DRUG MECHANISM; ENVIRONMENTAL EXPOSURE; GENE DUPLICATION; GENETIC ASSOCIATION; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; LEPROSY; LEWY BODY; MISSENSE MUTATION; MOLECULAR DYNAMICS; MOTOR DYSFUNCTION; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROPATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PARKINSON DISEASE; PH; POINT MUTATION; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN ISOLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; RISK FACTOR; SHY DRAGER SYNDROME; SMOKING; SUBSTANTIA NIGRA; TEMPERATURE DEPENDENCE;

ALPHA-SYNUCLEIN; ANIMALS; BIOPHYSICS; DEMENTIA; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, BIOLOGICAL; PARKINSON DISEASE; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING;

EID: 70349503591     PISSN: 13892037     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920309789351921     Document Type: Review

References (254)

1. Olanow, C.W.; Tatton, W.G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci., 1999, 22, 123-144.
2. Moghal, S.; Rajput, A.H.; D'Arcy, C.; Rajput, R. Prevalence of movement disorders in elderly community residents. Neuroepidemiology, 1994, 13, 175-178.
3. Fahn, S. Description of Parkinson's disease as a clinical syndrome. Ann. NY. Acad. Sci., 2003, 991, 1-44.
4. Tanner, C.M. Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. Adv. Neurol., 2003, 91, 133-142.
5. Farrer, M.J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev. Genet., 2006, 7, 306-318.
6. Mizuno, Y.; Hattori, N.; Kitada, T.; Matsumine, H.; Mori, H.; Shimura, H.; Kubo, S.; Kobayashi, H.; Asakawa, S.; Minoshima, S.; Shimizu, N. Familial Parkinson's disease: alpha-synuclein and parkin. Adv. Neurol., 2001, 86, 13-21.
7. Van Den Eeden, S.K.; Tanner, C.M.; Bernstein, A.L.; Fross, R.D.; Leimpeter, A.; Bloch, D.A.; Nelson, L.M. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol., 2003, 157, 1015-1022.
8. Lewy, F.H. In Paralysis Agitans. Pathologische Anatomie; Lewandowski M.; Ed.; Handbuch der Neurologie, Springer: Berlin, 1912, pp. 920-933.
9. Forno, L.S. Neuropathology of Parkinson's disease. J Neuropathol Exp. Neurol., 1996, 55, 259-272.
10. Okazaki, H.; Lipkin, L.E.; Aronson, S.M. Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol, 1961, 20, 237-244.
11. Trojanowski, J.Q.; Goedert, M.; Iwatsubo, T.; Lee, V.M. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Cell Death. Differ., 1998, 5, 832-837.
12. Takeda, A.; Mallory, M.; Sundsmo, M.; Honer, W.; Hansen, L.; Masliah, E. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am. J. Pathol., 1998, 152, 367-372.
13. Lucking, C.B.; Brice, A. Alpha-synuclein and Parkinson's disease. Cell. Mol. Life. Sci., 2000, 57, 1894-1908.
14. Tennyson, V.M. Electron microscopic study of the developing neuroblast of the dorsal root ganglion of the rabbit embryo. J. Comp. Neurol., 1965, 124, 267-317.
15. Zarranz, J.J.; Alegre, J.; Gomez-Esteban, J.C.; Lezeano, E.; Ros, R.; Ampuero, I.; Vidal, L.; Hoenicka, J.; Rodriguez, O.; Atares, B.; Llorens, V.; Gomez Tortosa, E.; del Ser, T.; Munoz, D.G.; de Yebenes, J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol., 2004, 55, 164-173.
16. Polymeropoulos, M.H.; Lavedan, C.; Leroy, E.; Ide, S.E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; Stenroos, E.S.; Chandrasekharappa, S.; Athanassiadou, A.; Papapetropoulos, T.; Johnson, W.G.; Lazzarini, A.M.; Duvoisin, R.C.; Di Iorio, G.; Golbe, L.I.; Nussbaum, R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 1997, 276, 2045-2047.
17. Kruger, R.; Kuhn, W.; Muller, T.; Woitalla, D.; Graeber, M.; Kosel, S.; Przuntek, H.; Epplen, J.T.; Schols, L.; Riess, O. Ala30Pm mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet., 1998, 18, 106-108.
18. Singleton, A.; Gwinn-Hardy, K.; Sharabi, Y.; Li, S.T.; Holmes, C.; Dendi, R.; Hardy, J.; Crawley, A.; Goldstein, D.S. Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. Brain, 2004, 127, 768-772.
19. Singleton, A.B.; Farrer, M.; Johnson, J.; Singleton, A.; Hague, S.; Kachergus, J.; Hulihan, M.; Peuralinna, T.; Dutra, A.; Nussbaum, R.; Lincoln, S.; Crawley, A.; Hanson, M.; Maraganore, D.; Adler, C.; Cookson, M.R.; Muenter, M.; Baptista, M.; Miller, D.; Blancato, J.; Hardy, J.; Gwinn-Hardy, K. alpha-Synuclein locus triplication causes Parkinson's disease. Science, 2003, 302, 841.
20. Farrer, M.; Kachergus, J.; Forno, L.; Lincoln, S.; Wang, D.S.; Hulihan, M.; Maraganore, D.; Gwinn-Hardy, K.; Wszolek, Z.; Dickson, D.; Langston, J.W. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol., 2004, 55, 174-179.
21. Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. Alpha-synuclein in Lewy bodies. Nature, 1997, 388, 839-840.
22. Spillantini, M.G.; Crowther, R.A.; Jakes, R.; Hasegawa, M.; Goedert, M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc. Natl. Acad. Sci. USA, 1998, 95, 6469-6473.
23. Masliah, E.; Rockenstein, E.; Veinbergs, I.; Mallory, M.; Hashimoto, M.; Takeda, A.; Sagara, Y.; Sisk, A.; Mucke, L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science, 2000, 287, 1265-1269.
24. Feany, M.B.; Bender, W.W. A Drosophila model of Parkinson's disease. Nature, 2000, 404, 394-398.
25. Trojanowski, J.Q.; Lee, V.M. Parkinson's disease and related alpha-synuclemopathies are brain amyloidoses. Ann. NY Acad. Sci., 2003, 991, 107-110.
26. Dickson, D.W. Alpha-synuclein and the Lewy body disorders. Curr. Opin Neurol, 2001, 14, 423-432.
27. Goedert, M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev Neurosci, 2001, 2, 492-501.
28. Goedert, M. Parkinson's disease and other alpha-synucleinopathies. Clin. Chem. Lab. Med., 2001, 39, 308-312.
29. Dev, K.K.; Hofele, K.; Barbieri, S.; Buchman, V.L.; van der Putten, H. Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology, 2003, 45, 14-44.
30. Uversky, V.N.; Fink, A.L. Amino acid determinants of alpha-synuclein aggregation: putting together pieces of the puzzle. FEBS Lett., 2002, 522, 9-13.
31. Uversky, V.N. Alpha-synuclein misfolding and neurodegenerative diseases. Curr. Protein Pept. Sci., 2008, 9, 507-540.
32. Uversky, V.N. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J. Neurochem., 2007, 103, 17-37.
33. Goedert, M. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synupleinopathies. Philos. Trans. R Soc. Land B Biol. Sci., 1999, 354, 1101-1118.
34. Spillantini, M.G.; Goedert, M. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann. NY Acad. Sci., 2000, 920, 16-27.
35. Galvin, J.E.; Lee, V.M.; Trojanowski, J.Q. Synuclemopathics: clinical and pathological implications. Arch. Neurol., 2001, 58, 186-190.
36. Spillantini, M.G.; Crowther, R.A.; Jakes, R.; Cairns, NJ.; Lantos, P.L.; Goedert, M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett., 1998, 251, 205-208.
37. Wakabayashi, K.; Yoshimoto, M.; Tsuji, S.; Takahashi, H. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci. Lett., 1998, 249, 180-182.
38. Gai, W.P.; Power, J.H.; Blumbergs, P.C.; Blessing, W.W. Multiple-system atrophy: a new alpha-synuclein disease? Lancet, 1998, 352, 547-548.
39. Arawaka, S.; Saito, Y.; Murayama, S.; Mori, H. Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein. Neurology, 1998, 51, 887-889.
40. Wakabayashi, K.; Matsumoto, K.; Takayama, K.; Yoshimoto, M.; Takahashi, H. NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci. Lett., 1997, 239, 45-48.
41. Lundvig, D.; Lindersson, E.; Jensen, P.H. Pathogenic effects of alpha-synuclein aggregation. Brain Res. Mol. Brain Res., 2005, 134, 3-17.
42. Kosaka, K. Lewy bodies in cerebral cortex, report of three cases. Acta Neuropathol. (Berl.), 1978, 42, 127-134.
43. Kosaka, K.; Yoshimura, M.; Ikeda, K.; Budka, H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree - a new disease? Clin. Neuropathol., 1984, 3, 185-192.
44. Deramecourt, V.; Bombois, S.; Maurage, C.A.; Ghestem, A.; Drobecq, H.; Vanmechelen, E.; Lebert, F.; Pasquier, F.; Delacourte, A. Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodid. J. Neuropathol. Exp. Neurol., 2006, 65, 278-288.
45. Galpern, W.R.; Lang, A.E. Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann. Neurol., 2006, 59, 449-458.
46. Mayeux, R.; Denaro, J.; Hemenegildo, N.; Marder, K.; Tang, M.X.; Cote, L.J.; Stern, Y. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch. Neurol., 1992, 49, 492-497.
47. Aarsland, D.; Andersen, K.; Larsen, J.P.; Lolk, A.; Nielsen, H.; Kragh-Sorensen, P. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology, 2001, 56, 730-736.
48. McKeith, I.G.; Dickson, D.W.; Lowe, J.; Emre, M.; O'Brien, J.T.; Feldman, H.; Cummings, J.; Duda, J.E.; Lippa, C.; Perry, E.K.; Aarsland, D.; Arai, H.; Ballard, C.G.; Boeve, B.; Bum, D.J.; Costa, D.; Del Ser, T.; Dubois, B.; Galasko, D.; Gauthier, S.; Goetz, C.G.; Gomez-Tortosa, E.; Halliday, G.; Hansen, L.A.; Hardy, J.; Iwatsubo, T.; Kalaria, R.N.; Kaufer, D.; Kenny, R.A.; Korczyn, A.; Kosaka, K.; Lee, V.M.; Lees, A.; Litvan, I.; Londos, E.; Lopez, O.L.; Minoshima, S.; Mizuno, Y.; Molina, J.A.; Mukaetova-Ladinska, E.B.; Pasquier, F.; Perry, R.H.; Schutz, J.B.; Trojanowski, J.Q.; Yamada, M. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology, 2005, 65, 1863-1872.
49. McKeith, I.G.; Galasko, D.; Kosaka, K.; Perry, E.K.; Dickson, D.W.; Hansen, L.A.; Salmon, D.P.; Lowe, J.; Mirra, S.S.; Byme, E.J.; Lennox, G.; Quinn, N.P.; Edwardson, J.A.; Ince, P.G.; Bergeron, C.; Burns, A.; Miller, B.L.; Lovestone, S.; Collerton, D.; Jansen, E.N.; Ballard, C.; de Vos, R.A.; Wilcock, G.K.; Jellinger, K.A.; Perry, R.H. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology, 1996, 47, 1113-1124.
50. McKeith, I.; Mintzer, J.; Aarsland, D.; Burn, D.; Chiu, H.; Cohen-Mansfield, J.; Dickson, D.; Dubois, B.; Duda, J.E.; Feldman, H.; Gauthier, S.; Halliday, G.; Lawlor, B.; Lippa, C.; Lopez, O.L.; Carlos Machado, J.; O'Brien, J.; Playfer, J.; Reid, W. Dementia with Lewy bodies. Lancet Neurol., 2004, 3, 19-28.
51. Emre, M, Dementia in Parkinson's disease: cause and treatment. Curr. Opin. Neurol., 2004, 17, 399-404.
52. Plato, C.C.; Cruz, M.T.; Kurland, L.T. Amyotrophic lateral sclerosis-Parkinsonism dementia complex of Guam: further genetic investigations. Am. J. Hum. Genet., 1969, 21, 133-141.
53. Schmitt, H.P.; Emser, W.; Heimes, C. Familial occurrence of amyotrophic lateral sclerosis, parkinsonism, and dementia. Ann. Neurol., 1984, 16, 642-648.
54. Spencer, P.S.; Nunn, P.B.; Hugon, J.; Ludolph, A.C.; Ross, S.M.; Roy, D.N.; Robertson, R.C. Guam amyotropbic lateral sclerosis-parkinsonism-dementia linked to a plant excitant neurotoxin. Science, 1987, 237, 517-522.
55. Stone, R. Guam: deadly disease dying out. Science, 1993, 261, 424-426.
56. Steele, J.C,; McGeer, P.L. The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology, 2008, 70, 1984-1990.
57. Majoor-Krakauer, D.; Ottman, R.; Johnson, W.G.; Rowland, L.P. Familial aggregation of amyotrophic lateral sclerosis, dementia, and Parkinson's disease: evidence of shared genetic susceptibility. Neurology, 1994, 44, 1872-1877.
58. Sebeo, J.; Hof, P.R.; Perl, D.P. Occurrence of alpha-synuclein pathology in the cerebellum of Guamanian patients with parkinsonism-dementia complex. Acta Neuropathol., 2004, 107, 497-503.
59. den Hartog Jager, W.A.; Bethlem, J. The distribution of Lewy bodies in the central and autonomic nervous systems in idiopathic paralysis agitans. J. Neurol. Neurosurg. Psychiatry, 1960, 23, 283-290.
60. Kosaka, K.; Mehraein, P. Dementia-Parkinsonism syndrome with numerous Lewy bodies and senile plaques in cerebral cortex. Arch. Psychiatr. Nervenkr., 1979, 226, 241-250.
61. McKhann, G.; Drachman, D.; Folstein, M.; Katzman, R.; Price, D.; Stadlan, E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 1984, 34, 939-944.
62. Clark, C.M.; Ewbank, D.; Lee, V.M.-Y.; Trojanowski, J.Q. In: Molecular Pathology of Alzheimer's Disease: Neuronal Cytoskeletal Abnormalities, Growdon, J.H.; Rossor, M.N. (Eds.), The Dementias. Vol. 19 of Blue Books of Practical Neurology, Butterworth-Heinemann: Boston, 1998, pp. 285-304.
63. Arai, Y.; Yamazaki, M.; Mori, O.; Muramatsu, H.; Asano, G.; Katayama, Y. Alpha-synuclein-positive structures in cases with sporadic Alzheimer's disease: morphology and its relationship to tau aggregation. Brain Res., 2001, 888, 287-296.
64. Lippa, C.F.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q. Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann. Neurol., 1999, 45, 353-357.
65. Marui, W.; Iseki, E.; Ueda, K.; Kosaka, K. Occurrence of human alpha-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer's disease. J. Neurol. Sci., 2000, 174, 81-84.
66. Daniel, S. In: The Neuropathology and Neurochemistry of Multiple System Atrophy, Mathias, C.J.; Bannister, R.; Eds.; Autonomic Failure, Oxford University Press: Oxford, 1999, pp. 321-328.
67. Papp, M.I.; Kahn, J.E.; Lantos, P.L. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J. Neurol. Sci., 1989, 94, 79-100.
68. Wakabayashi, K.; Takahashi, H. Cellular pathology in multiple system atrophy. Neuropathology, 2006, 26, 338-345.
69. Taylor, T.D.; Litt, M.; Kramer, P.; Pandolfo, M.; Angelini, L.; Nardocci, N.; Davis, S.; Pineda, M.; Hattori, H.; Flett, P.J.; Cilio, M.R.; Bertini, E.; Hayflick, S.J. Homozygosity mapping of Haller-vorden-Spatz syndrome to chromosome 20p12.3-pl3. Nat. Genet., 1996, 14, 479-481.
70. Malandrini, A.; Cesaretti, S.; Mulinari, M.; Palmeri, S., Fabrizi, G.M.; Villanova, M.; Parrotta, E.; Montagnani, A.; Montagnani, M.; Anichini, M.; Guazzi, G.C. Acanthocytosis, retinitis pigmentosa, pallidal degeneration. Report of two cases without serum lipid abnormalities. J Neurol. Sci., 1996, 140, 129-131.
71. Sugiyama, H.; Hainfellner, J.A.; Schmid-Siegel, B.; Budka, H. Neuroaxonal dystrophy combined with diffuse Lewy body disease in a young adult. Clin. Neuropathol., 1993, 12, 147-152.
72. Swaiman, K.F. Hallervorden-Spatz syndrome and brain iron metabolism. Arch. Neurol., 1991, 48, 1285-1293.
73. Dooling, E.C.; Schoene, W.C.; Richardson, E.P.; Jr. Hallervorden-Spatz syndrome. Arch. Neurol., 1974, 30, 70-83.
74. Jankovic, J.; Kirkpatrick, J.B.; Blomquist, K.A.; Langlais, P.J.; Bird, E.D. Late-onset Hallervorden-Spatz disease presenting as familial parkinsonism. Neurology, 1985, 35, 227-234.
75. Tu, P.H.; Galvin, J.E.; Baba, M.; Giasson, B.; Tomita, T.; Leight, S.; Nakajo, S.; Iwatsubo, T.; Trojanowski, J.Q.; Lee, V.M. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann. Neurol., 1998, 44, 415-422.
76. Wakabayashi, K.; Yoshimoto, M.; Fukushima, T.; Koide, R.; Horikawa, Y.; Morita, T.; Takahashi, H. Widespread occurrence of alpha-synuclein/ NACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies. Neuropathol. Appl. Neurobiol., 1999, 25, 363-368.
77. Galvin, J.E.; Giasson, B.; Hurtig, H.I.; Lee, V.M.; Trojanowski, J.Q. Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. Am. J. Pathol., 2000, 157, 361-368.
78. Neumann, M.; Adler, S.; Schluter, O.; Kremmer, E.; Benecke, R.; Kretzschmar, H.A. Alpha-synuclein accumulation in a case of neurodegeneration with brain iron accumulation type 1 (NBIA-1, formerly Hallervorden-Spatz syndrome) with widespread cortical and brainstem-type Lewy bodies. Acta Neuropathol. (Berl.), 2000, 100, 568-574.
79. Iwai, A.; Masliah, E.; Yoshimoto, M.; Ge, N.; Flanagan, L.; de Silva, H.A.; Kittel, A.; Saitoh, T. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron, 1995, 14, 467-475.
80. Payton, J.E.; Perrin, R.J.; Clayton, D.F.; George, J.M. Protein-protein interactions of alpha-synuclein in brain homogenates and transfected cells. Brain Res. Mol. Brain Res., 2001, 95, 138-145.
81. Jin, J.; Li, G.J.; Davis, J.; Zhu, D.; Wang, Y.; Pan, C.; Zhang, J. Identification of novel proteins interacting with both a-synuclein and DJ-1. Mol. Cell. Proteomics, 2006.
82. Betarbet, R.; Sherer, T.B.; MacKenzie, G.; Garcia-Osuna, M.; Panov, A.V.; Greenamyre, J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci., 2000, 3, 1301-1306.
83. da Costa, C.A.; Ancolio, K.; Checler, F. Wild-type but not Parkinson's disease-related ala-53 → Thr mutant alpha -synuclein protects neuronal cells from apoptotic stimuli. J. Biol. Chem., 2000, 275, 24065-24069.
84. Weinreb, P.H.; Zhen, W.; Poon, A.W.; Conway, K.A.; Lansbury, P.T.; Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry, 1996, 35, 13709-13715.
85. Uversky, V.N.; Li, J.; Fink, A.L. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem., 2001, 276, 10737-10744.
86. Uversky, V.N.; Li, J.; Souillac, P.; Millett, I.S.; Doniach, S.; Jakes, R.; Goedert, M.; Fink, A.L. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J. Biol. Chem., 2002, 277, 11970-11978.
87. Morar, A.S.; Olteanu, A.; Young, G.B.; Pielak, G.J. Solvent-induced collapse of alpha-synuclein and acid-denatured cytochrome c. Protein Sci., 2001, 10, 2195-2199.
88. Lattman, E.E. Small angle X-ray scattering studies of protein folding. Curr. Opin. Struct. Biol., 1994, 4, 87-92.
89. Kataoka, M.; Goto, Y. X-ray solution scattering studies of protein folding. Fold. Des., 1996, 1, R107-114.
90. Kataoka, M.; Hagihara, Y.; Mihara, K.; Goto, Y. Molten globule of cytochrome c studied by small angle X-ray scattering. J. Mol. Biol., 1993, 229, 591-596.
91. Kataoka, M.; Nishii, I.; Fujisawa, T.; Ueki, T.; Tokunaga, F.; Goto, Y. Structural characterization of the molten globule and native states of apomyoglobin by solution X-ray scattering. J. Mol. Biol., 1995, 249, 215-228.
92. Semisotnov, G.V.; Kihara, H.; Kotova, N.V.; Kimura, K.; Amemiya, Y.; Wakabayashi, K.; Serdyuk, I.N.; Timchenko, A.A.; Chiba, K.; Nikaido, K.; Ikura, T.; Kuwajima, K. Protein globularization during folding: a study by synchrotron small-angle X-ray scattering. J. Mol. Biol., 1996, 262, 559-574.
93. Kataoka, M.; Kuwajima, K.; Tokunaga, F.; Goto, Y. Structural characterization of the molten globule of alpha-lactalbumin by solution X-ray scattering. Protein Sci., 1997, 6, 422-430.
94. Uversky, V.N.; Karnoup, A.S.; Segel, D.J.; Seshadri, S.; Doniach, S.; Fink, A.L. Anion-induced folding of Staphylococcal nuclease: characterization of multiple equilibrium partially folded intermediates. J. Mol. Biol., 1998, 278, 879-894.
95. Hagihara, Y.; Hoshino, M.; Hamada, D.; Kataoka, M.; Goto, Y. Chain-like conformation of heat-denatured ribonuclease A and cytochrome c as evidenced by solution X-ray scattering. Fold. Des., 1998, 3, 195-201.
96. Uversky, V.N.; Gillespie, J.R.; Millett, I.S.; Khodyakova, A.V.; Vasiliev, A.M.; Chemovskaya, T.V.; Vasilenko, R.N.; Kozlovskaya, G.D.; Dolgikh, D.A.; Fink, A.L., Donjach, S.; Abramov, V.M. Natively unfolded human prothymosin alpha adopts partially folded collapsed conformation at acidic pH. Biochemistry, 1999, 38, 15009-15016.
97. Uversky, V.N.; Gillespie, J.R.; Millett, I.S.; Khodyakova, A.V.; Vasilenko, R.N.; Vasiliev, A.M,; Rodionov, I.L.; Kozlovskaya, G.D.; Dolgikh, D.A.; Fink, A.L.; Doniach, S.; Permyakov, E.A.; Abramov, V.M. Zn(2+)-mediated structure formation and compaction of the "natively unfolded" human prothymosin alpha. Biochem. Biophys. Res. Commun., 2000, 267, 663-668.
98. Doniach, S. Changes in biomolecular conformation seen by small angle X-ray scattering. Chem. Rev., 2001, 101, 1763-1778.
99. Bussell, R.Jr.; Eliezer, D. Residual structure and dynamics in Parkinson's disease-associated mutants of alpha-synuclein. J. Biol. Chem., 2001, 276, 45996-46003.
100. Dedmon, M.M.; Lindorff-Larsen, K.; Christodoulou, J.; Vendruscolo, M.; Dobson, C.M. Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. J. Am. Chem. Soc., 2005, 127, 476-477.
101. Bertoncim, C.W.; Jung, Y.S.; Fernandez, C.O.; Hoyer, W.; Griesinger, C.; Jovin, T.M.; Zweckstetter, M. Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc. Natl. Acad Sci. USA, 2005, 102, 1430-1435.
102. Sung, Y.H.; Eliezer, D. Residual structure, backbone dynamics, and interactions within the symiclein family. J Mol. Biol., 2007, 372, 689-707.
103. Uversky, V.N.; Gillespie, J.R.; Fink, A.L. Why are "natively unfolded" proteins unstructured under physiologic conditions? Proteins, 2000, 41, 415-427.
104. Uversky, V.N. Natively unfolded proteins: a point where biology waits for physics. Protein Sci., 2002, 11, 739-756.
105. Uversky, V.N. What does it mean to be natively unfolded? Eur. J. Biochem., 2002, 269, 2-12.
106. Uversky, V.N. Protein folding revisited: a polypeptide chain at the folding-misfolding-nonfolding cross-roads: which way to go? Cell. Mol. Life Sci., 2003, 60, 1852-1871.
107. Dyson, H.J.; Wright, P.E. Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell. Biol., 2005, 6, 197-208.
108. Li, J.; Uversky, V.N.; Fink, A.L. Conformational behavior of human alpha-symiclein is modulated by familial Parkinson's disease point mutations A30P and A53T. Neurotoxicology, 2002, 23, 553-567.
109. Conway, K.A.; Harper, J.D.; Lansbury, P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med., 1998, 4, 1318-1320.
110. El-Agnaf, O.M.; Jakes, R.; Curran, M.D.; Wallace, A. Effects of the mutations Ala3O to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease. FEBS Lett., 1998, 440, 67-70.
111. Narhi, L.; Wood, S.J.; Steavenson, S.; Jiang, Y.; Wu, G.M.; Anafi, D.; Kaufman, S.A.; Martin, F.; Sitney, K.; Denis, P.; Louis, J.C.; Wypych, J.; Biere, A.L.; Citron, M. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem., 1999, 274, 9843-9846.
112. Giasson, B.I.; Uryu, K.; Trojanowski, J.Q.; Lee, V.M. Mutant and wild type, human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem., 1999, 274, 7619-7622.
113. Conway, K.A.; Harper, J.D.; Lansbury, P.T.; Jr. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry, 2000, 39, 2552-2563.
114. Conway, K.A.; Lee, S.J.; Rochet, J.C.; Ding, T.T.; Harper,; J.D.; Williamson, R.E.; Lansbury, P.T.; Jr. Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. Ann. NY Acad. Sci., 2000, 920, 42-45.
115. Conway, K.A.; Lee, S.J.; Rochet, J.C.; Ding, T.T.; Williamson, R.E.; Lansbury, P.T.; Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA, 2000, 97, 571-576.
116. Li, J.; Uversky, V.N.; Fink, A.L. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry, 2001, 40, 11604-11613.
117. Greenbaum, E.A.; Graves, C.L.; Mishizen-Eberz, A.J.; Lupoli, M.A.; Lynch, DR.; Englander, S.W.; Axelsen, P.H.; Giasson, B.I. The B46K mutation in alpha-synuclein increases amyloid fibril formation. J. Blol. Chem., 2005, 280, 7800-7807.
118. Fredenburg, R.A.; Rospigliosi, C.; Meray, R.K.; Kessler, J.C.; Lastuel, H.A.; Eliezer, D.; Lansbury, P.T.; Jr. The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry, 2007, 46, 7107-7118.
119. Bertoncini, C.W.; Fernandez, C.O.; Griesinger, C.; Jovin, T.M.; Zweckstetter, M. Familial mutants of alpha-synuclein with increased neurotoxicity have a destabilized conformation. J. Biol. Chem., 2005, 280, 30649-30652.
120. Perrin, R.J.; Woods, W.S.; Clayton, D.F.; George, J.M. Interaction of human alpha-Synucleih and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis. J. Biol. Chem., 2000, 275, 34393-34398.
121. Davidson, W.S.; Jonas, A.; Clayton, D.F.; George, J.M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem., 1998, 273, 9443-9449.
122. Bussell, R.; Jr.; Eliezer, D. A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. J. Mol. Biol., 2003, 329, 763-778.
123. Chandra, S.; Chen, X.; Rizo, J.; Jahn, R.; Sudhof, T.C. A broken alpha -helix in folded alpha -Synuclein. J. Biol. Chem., 2003, 278, 15313-15318.
124. Bussell, R.; Jr.; Ramlall, T.F.; Eliezer, D. Helix periodicity, topology, and dynamics of membrane-associated alpha-synuclein. Protein Sci., 2005, 14, 862-872.
125. Ulmer, T.S.; Bax, A.; Cole, N.B.; Nussbaum, R.L. Structure and dynamics of micelle-bound human alpha-synuclein. J. Biol. Chem., 2005, 280, 9595-9603.
126. Eliezer, D.; Kutluay, E.; Bussell, R.; Jr.; Browne, G. Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol Biol., 2001, 307, 1061-1073.
127. Jan, C.C.; Der-Sarkissian, A.; Chen, J.; Langen, R. Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. Proc. Natl. Acad. Sci. USA, 2004, 101, 8331-8336.
128. Borbat, P.; Ramlall, T.F.; Freed, J.H.; Eliezer, D. Inter-helix distances in lysophospholipid micelle-bound alpha-synuclein from pulsed ESR measurements. J. Am. Chem. Soc., 2006, 128, 10004-10005.
129. Georgieva, E.R.; Ramlall, T.F.; Borbat, P.P.; Freed, J.H.; Eliezer, D. Membrane-bound alpha-symiclein forms an extended helix: long-distance pulsed ESR measurements using vesicles, bicelles, and rodlike micelles. J. Am. Chem. Soc., 2008, 130, 12856-12857.
130. Eliezer, D. In Protein Folding and Aggregation in In Vitro Models of Parkinson's Disease: Structure and Function of Alpha-Synuclein, Nash, R.; Przedborski, S.; Eds.; Parkinson's Disease: Pathogenic and Therapeutic Insightsfrom Toxin and Genetic Models, Academic Press: New York, 2008, pp. 575-595.
131. Yamin, G.; Glaser, C.B.; Uversky, V.N.; Fink, A.L. Certain metals trigger fibrillation of methionme-oxidized alpha-synuclein. J. Biol, Chem., 2003, 278, 27630-27635.
132. Cohlberg, J.A.; Li, J.; Uversky, V.N.; Fink, A.L. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. Biochemistry, 2002, 41, 1502-1511.
133. Glaser, C.B.; Yamin, G.; Uversky, V.N.; Fink, A.L. Methionine oxidation, alpha-synuclein and Parkinson's disease, Biochim. Biophys. Acta, 2005, 1703, 157-169.
134. Munishkina, L.A.; Phelan, C.; Uversky, V.N.; Fink, A.L. Conformational behavior and aggregation of alpha-synuclein in organic solvents: modeling the effects of membianes. Biochemistry, 2003, 42, 2720-2730.
135. Uversky, V.N.; Li, J.; Fink, A.L. Trimethylamine-N-oxide-induced folding of alpa-synuclein. FEBS Lett., 2001, 509, 31-35.
136. Uversky, V.N.; Li, J.; Fink, A.L. Metal-triggered structural transformations aggregation, and fibrillation of human alpha-synuclein: a possible molecular NK between Parkinson's disease and heavy metal exposure. J. -Biol. Chem., 2001, 276, 44284-44296.
137. Munishkini, L.A.; Henriques, J.; UVersky, V.N.; Fink, A.L. Role of protein-water interactions and electrostatics in alpha-synuclein fibril formation. Biochemistry, 2004, 43, 3289-3300.
138. Uversky, V.N.; Li, J.; Fink, A.L. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease. FEBS Lett., 2001, 500, 105-108.
139. Uversky, V.N.; Li, J.; Bower, K.; Fink, A.L. Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson's disease. Neurotoxicology, 2002, 23, 527-536.
140. Manning-Bog, A.B.; McCormack, A.L.; Li, J.; Uversky, V.N.; Fink, A.L.; Di Monte, D.A. The herbicide paraquat causes upregulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem., 2002, 277, 1641-1644.
141. Goers, J.; Uversky, V.N.; Fink, A.L. Polycation-induced oligomerization and accelerated fibrillation of human alpha-synuclein in vitro. Protein Sci, 2003, 12, 702-707.
142. Uversky, V.N.; Lee, H.J.; Li, J.; Fink, A.L.; Lee, S.J. Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. J. Biol. Chem., 2001, 276, 43495-43498.
143. Souza, J.M.; Giasson, B.I.; Chen, Q.; Lee, V.M.; Ischiropoulos, H. Dityrosine cross-linking promotes formation of stable alpha - synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem., 2000, 275, 18344-18349.
144. Yamin, G.; Uversky, V.N.; Fink, A.L. Nitration inhibits fibrillation of human alpha-synuclein in vitro by formation of soluble oligomers. FEBS Lett., 2003, 542, 147-152.
145. Lowe, R.; Pountney, D.L.; Jensen, P.H.; Gai, W.P.; Voelcker, N.H. Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain. Protein Sci., 2004, 13, 3245-3252.
146. Uversky, V.N. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J. Biomol. Struct. Dyn., 2003, 21, 211-234.
147. Fink, A.L. The aggregation and fibrillation of alpha-synuclein. Acc. Chem. Res., 2006, 39, 628-634.
148. Choi, W.; Zibaee, S.; Jakes, R.; Serpell, L.C.; Davletov, B.; Crowther, R.A.; Goedert, M. Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett., 2004, 576, 363-368.
149. Zimmerman, S.B.; Trach, S.O. Estimation of macromolecule concentrations and excluded volume effects for the cytoplasm of Escherichia coli. J. Mol. Biol., 1991, 222, 599-620.
150. Minton, A.P. The influence of macromolecular crowding and macromolecular confinement on biochemical reactions in physiological media. J. Biol. Chem., 2001, 276, 10577-10580.
151. Minton, A.P. Implications of macromolecular crowding for protein assembly. Curr. Opin. Struct. Biol., 2000, 10, 34-39.
152. Uversky, V.N.; Cooper, E.M.; Bower, K.S.; Li, J.; Fink, A.L. Accelerated alpha-synuclein fibrillation in crowded milieu. FEBS Lett., 2002, 515, 99-103.
153. Shtilerman, M.D.; Ding, T.T.; Lansbury, P.T.; Jr. Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease? Biochemistry, 2002, 41, 3855-3860.
154. Munishkina, L.A.; Cooper, E.M.; Uversky, V.N.; Fink, A.L. The effect of macromolecular crowding on protein aggregation and amyloid fibril formation. J. Mol. Recognit., 2004, 17, 456-464.
155. Munishkina, L.A.; Fink, A.L.; Uversky, V.N. Concerted action of metals and macromolecular crowding on the fibrillation of alpha-synuclein. Protein Pept. Lett., 2008, 15, 1079-1085.
156. Munishkina, L.A.; Ahmad, A.; Fink, A.L.; Uversky, V.N. Guiding protein aggregation with macromolecular crowding. Biochemistry, 2008, 47, 8993-9006.
157. Kisilevsky, R. Review: amyloidogenesis-unquestioned answers and unanswered questions. J. Struct. Biol., 2000, 130, 99-108.
158. McLaurin, J.; Yang, D.; Yip, C.M.; Fraser, P.E. Review: modulating factors in amyloid-beta fibril formation. J. Struct. Biol., 2000, 130, 259-270.
159. Tsen, G.; Halfter, W.; Kroger, S.; Cole, G.J. Agrin is a heparan sulfate proteoglycan. J. Biol. Chem., 1995, 270, 3392-3399.
160. Halfter, W.; Schurer, B.; Yip, J.; Yip, L.; Tsen, G.; Lee, J.A.; Cole, G.J. Distribution and substrate properties of agrin, a heparan sulfate proteoglycan of developing axonal pathways. J. Comp. Neurol., 1997, 383, 1-17.
161. Cohen, N.A.; Kaufmann, W.E.; Worley, P.F.; Rupp, F. Expression of agrin in the developing and adult rat brain. Neuroscience, 1997, 76, 581-596.
162. Liu, I.H.; Uversky, V.N.; Munishkina, L.A.; Fink, A.L.; Halfter, W.; Cole, G.J. Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation. Glycobiology, 2005, 15, 1320-1331.
163. Goers, J.; Manning-Bog, A.B.; McCormack, A.L.; Millett, I.S.; Doniach, S.; Di Monte, D.A.; Uversky, V.N.; Fink, A.L. Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry, 2003, 42, 8465-8471.
164. Tanner, C.M. The role of environmental toxins in the etiology of Parkinson's disease. Trends Neurosci., 1989, 12, 49-54.
165. Tanner, C.M.; Chen, B.; Wang, W.; Peng, M.; Liu, Z.; Liang, X.; Kao, L.C.; Gilley, D.W.; Goetz, C.G.; Schoenberg, B.S. Environmental factors and Parkinson's disease: a case-control study in China. Neurology, 1989, 39, 660-664.
166. Di Monte, D.A. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol., 2003, 2, 531-538.
167. McCormack, A.L.; Thiruchelvam, M.; Manning-Bog, A.B.; Thiffault, C.; Langston, J.W.; Cory-Slechta, D.A.; Di Monte, D.A. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis., 2002, 10, 119-127.
168. Di Monte, D.A.; Lavasani, M.; Manning-Bog, A.B. Environmental factors in Parkinson's disease. Neurotoxicology, 2002, 23, 487-502.
169. Di Monte, D.A. The role of environmental agents in Parkinson's disease. Clin. Neurosci. Res., 2001, 1, 419-426.
170. Uversky, V.N. Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell. Tissue Res., 2004, 318, 225-241.
171. Gorell, J.M.; Johnson, C.C.; Rybicki, B.A.; Peterson, E.L.; Kortsha, G.X.; Brown, G.G.; Richardson, R.J. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology, 1999, 20, 239-247.
172. Altschuler, E. Aluminum-containing antacids as a cause of idiopathic Parkinson's disease. Med. Hypotheses, 1999, 53, 22-23.
173. Zayed, J.; Ducic, S.; Campanella, G.; Panisset, J.C.; Andre, P.; Masson, H.; Roy, M. Environmental factors in the etiology of Parkinson's disease. Can. J. Neurol. Sci., 1990, 17, 286-291.
174. Gorell, J.M.; Rybicki, B.A.; Johnson, C.C.; Peterson, E.L. Occupational metal exposures and the risk of Parkinson's disease. Neuroepidemiology, 1999, 18, 303-308.
175. Rybicki, B.A.; Johnson, C.C.; Uman, J.; Gorell, J.M. Parkinson's disease mortality and the industrial use of heavy metals in Michigan. Mov. Disord., 1993, 8, 87-92.
176. Hirsch, E.C.; Brandel, J.P.; Galle, P.; Javoy-Agid, F.; Agid, Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem., 1991, 56, 446-451.
177. Riederer, P.; Sofic, E.; Rausch, W.D.; Schmidt, B.; Reynolds, G.P.; Jellinger, K.; Youdim, M.B. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem., 1989, 52, 515-520.
178. Dexter, D.T.; Carayon, A.; Javoy-Agid, F.; Agid, Y.; Wells, F.R.; Daniel, S.E.; Lees, A.J.; Jenner, P.; Marsden, C.D. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain, 1991, 114 (Pt 4), 1953-1975.
179. Sung, Y.H.; Rospigliosi, C.; Eliezer, D. NMR mapping of copper binding sites in alpha-synuclein. Biochim. Biophys. Acta, 2006, 1764, 5-12.
180. Seidler, A.; Hellenbrand, W.; Robra, B.P.; Vieregge, P.; Nischan, P.; Joerg, J.; Oertel, W.H.; Ulm, G.; Schneider, E. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. Neurology, 1996, 46, 1275-1284.
181. Davis, L.E.; Adair, J.C. Parkinsonism from methanol poisoning: benefit from treatment with anti-Parkinson drugs. Mov. Disord., 1999, 14, 520-522.
182. Hageman, G.; van der Hoek, J.; van Hout, M.; van der Laan, G.; Steur, E.J.; de Bruin, W.; Herholz, K. Parkinsonism, pyramidal signs, polyneuropathy, and cognitive decline after long-term occupational solvent exposure. J. Neurol., 1999, 246, 198-206.
183. Pezzoli, G.; Strada, O.; Silani, V.; Zecchinelli, A.; Perbellini, L.; Javoy-Agid, F.; Ghidoni, P.; Motti, E.D.; Masini, T.; Scarlato, G.; Agid, Y.; Hirsch, E.C. Clinical and pathological features in hydrocarbon-induced parkinsonism. Ann. Neurol., 1996, 40, 922-925.
184. Uitti, R.J., Snow, B.J.; Shmotoh, H.; Vingerhoets, F.J.; Hayward, M.; Hashimoto, S.; Richmond, I.; Markey, S.P.; Markey, C.J.; Calne, D.B. Parkinsonism induced by solvent abuse. Ann. Neurol., 1994, 35, 616-619.
185. Markesbery, W.R. The role of oxidative stress in Alzheimer disease. Arch. Neurol., 1999, 56, 1449-1452.
186. Markesbery, W.R.; Carney, J.M. Oxidative alterations in Alzheimer's disease. Brain Pathol., 1999, 9, 133-146.
187. Duda, J.E.; Giasson, B.I.; Chen, Q.; Gur, T.L.; Hurtig, H.I.; Stern, M.B.; Gollomp, S.M.; Ischiropoulos, H.; Lee, V.M.; Trojanowski, J.Q. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am. J. Pathol., 2000, 157, 1439-1445.
188. Lyras, L.; Perry, R.H.; Perry, E.K.; Ince, P.G.; Jenner, A.; Jenner, P.; Halliwell, B. Oxidative damage to proteins, lipids, and DNA in cortical brain regions from patients with dementia with Lewy bodies. J Neurochem, 1998, 71, 302-312.
189. Cookson, M.R.; Shaw, P.J. Oxidative stress and motor neurone disease. Brain Pathol., 1999, 9, 165-186.
190. Browne, S.E.; Ferrante, R.J.; Beal, M.F. Oxidative stress in Huntington's disease. Brain Pathol., 1999, 9, 147-163.
191. Witko-Sarsat, V.; Khoa, T.N.; Jungers, P.; Drueke, T.; Descamps-Latscha, B. Advanced oxidation protein products: oxidative stress markers and mediators of inflammation in uremia. Adv. Nephrol Necker. Hosp., 1998, 28, 321-341.
192. Witko-Sarsat, V.; Friedlander, M.; Nguyen Khoa, T.; Capeillere-Blandin, C.; Nguyen, A.T.; Canteloup, S.; Dayer, J.M.; Jungers, P.; Drueke, T.; Descamps-Latscha, B. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J. Immunol., 1998, 161, 2524-2532.
193. Fu, S.; Dean, R.; Southan, M.; Truscott, R. The hydroxyl radical in lens nuclear cataractogenesis. J. Biol. Chem., 1998, 273, 28603-28609.
194. Floyd, R.A. Role of oxygen free radicals in carcinogenesis and brain ischemia. FASEB J., 1990, 4, 2587-2597.
195. Smith, C.D.; Carney, J.M.; Starke-Reed, P.E.; Oliver, C.N.; Stadtman, E.R.; Floyd, R.A.; Markesbery, W.R. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1991, 88, 10540-10543.
196. Stadtman, E.R.; Oliver, C.N.; Starke-Reed, P.E.; Rhee, S.G. Age-related oxidation reaction in proteins. Toxicol. Ind. Health, 1993, 9, 187-196.
197. Leeuwenburgh, C.; Hansen, P.; Shaish, A.; Holloszy, J.O.; Heinecke, J.W. Markers of protein oxidation by hydroxyl radical and reactive nitrogen species in tissues of aging rats. Am. J. Physiol., 1998, 274, R453-461.
198. Uversky, V.N.; Yamin, G.; Souillac, P.O.; Goers, J.; Glaser, C.B.; Fink, A.L. Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. FEBS Lett, 2002, 517, 239-244.
199. Hokenson, M.J.; Uversky, V.N.; Goers, J.; Yamin, G.; Munishkina, L.A.; Fink, A.L. Role of individual methionines in the fibrillation of methionine-oxidized alpha-synuclein. Biochemistry, 2004, 43, 4621-4633.
200. Tompkins, M.M.; Hill, W.D. Contribution of somal Lewy bodies to neuronal death. Brain Res., 1997, 775, 24-29.
201. Arrasate, M.; Mitra, S.; Schweitzer, E.S.; Segal, M.R.; Finkbeiner, S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature, 2004, 431, 805-810.
202. Urbanc, B.; Cruz, L.; Le, R.; Sanders, J.; Ashe, K.H.; Duff, K.; Stanley, H.E.; Irizarry, M.C.; Hyman, B.T. Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2002, 99, 13990-13995.
203. Mucke, L.; Masliah, E.; Yu, G.Q.; Mallory, M.; Rockenstein, E.M.; Tatsuno, G.; Hu, K.; Kholodenko, D.; Johnson-Wood, K.; McConlogue, L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci., 2000, 20, 4050-4058.
204. Lashuel, H.A.; Petre, B.M.; Wall, J.; Simon, M.; Nowak, R.J.; Walz, T.; Lansbury, P.T.; Jr. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol., 2002, 322, 1089-1102.
205. Lashuel, H.A.; Hartley, D.; Petre, B.M.; Walz, T.; Lansbury, P.T.; Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature, 2002, 418, 291.
206. Caughey, B.; Lansbury, P.T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci., 2003, 26, 267-298.
207. Walsh, D.M.; Selkoe, D.J. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept. Lett., 2004, 11, 213-228.
208. Eliezer, D. Amyloid ion channels: a porous argument or a thin excuse? J. Gen. Physiol., 2006, 128, 631-633.
209. Sokolov, Y.; Kozak, J.A.; Kayed, R.; Chanturiya, A.; Glabe, C.; Hall, J.E. Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J. Gen. Physiol., 2006, 128, 637-647.
210. Ischiropoulos, H. Biological significance and clinical relevance of nitric oxide-mediated protein modifications. Free Radic. Res., 2003, 37, 15.
211. Ischiropoulos, H. Biological selectivity and functional aspects of protein tyrosine nitration. Biochem. Biophys. Res. Commun., 2003, 305, 776-783.
212. Ischiropoulos, H. Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species. Arch. Biochem. Biophys., 1998, 356, 1-11.
213. Giasson, B.I.; Duda, J.E.; Murray, I.V.; Chen, Q.; Souza, J.M.; Hurtig, H.I.; Ischiropoulos, H.; Trojanowski, J.Q.; Lee, V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science, 2000, 290, 985-989.
214. Uversky, V.N.; Yamin, G.; Munishkina, L.A.; Karymov, M.A.; Millett, I.S.; Doniach, S.; Lyubchenko, Y.L.; Fink, A.L. Effects of nitration on the structure and aggregation of alpha-synuclein. Brain Res. Mol. Brain Res., 2005, 134, 84-102.
215. Qin, Z.; Hu, D.; Han, S.; Reaney, S.H.; Di Monte, D.A.; Fink, A.L. Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J. Biol. Chem., 2007, 282, 5862-5870.
216. Hashimoto, M.; Rockenstein, E.; Mante, M.; Mallory, M.; Masliah, E. beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron, 2001, 32, 213-223.
217. Zhou, W.; Zhu, M.; Wilson, M.A.; Petsko, G.A.; Fink, A.L. The oxidation state of DJ-1 regulates its chaperone activity toward alpha-synuclein. J. Mol. Biol., 2006, 356, 1036-1048.
218. Shendelman, S.; Jonason, A.; Martinat, C.; Leete, T.; Abeliovich, A. DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol., 2004, 2, e362.
219. Maroteaux, L.; Campanelli, J.T.; Scheller, R.H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci., 1988, 8, 2804-2815.
220. Jensen, P.H.; Nielsen, M.S.; Jakes, R.; Dotti, C.G.; Goedert, M. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J. Biol. Chem., 1998, 273, 26292-26294.
221. Jenco, J.M.; Rawlingson, A.; Daniels, B.; Morris, A.J. Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry, 1998, 37, 4901-4909.
222. Clayton, D.F.; George, J.M. Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res., 1999, 58, 120-129.
223. Clayton, D.F.; George, J.M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends. Neurosci., 1998, 21, 249-254.
224. Cole, N.B.; Murphy, D.D.; Grider, T.; Rueter, S.; Brasaemle, D.; Nussbaum, R.L. Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. J. Biol. Chem., 2002, 277, 6344-6352.
225. Rhoades, E.; Ramlall, T.F.; Webb, W.W.; Eliezer, D. Quantification of alpha-synuclein binding to lipid vesicles using fluorescence correlation spectroscopy. Biophys. J., 2006, 90, 4692-4700.
226. Lee, H.J.; Choi, C.; Lee, S.J. Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem., 2002, 277, 671-678.
227. George, J.M. The synucleins. Genome. Biol., 2002, 3, REVIEWS 3002.
228. Zhu, M.; Fink, A.L. Lipid binding inhibits alpha-synuclein fibril formation. J. Biol. Chem., 2003, 278, 16873-16877.
229. Zhu, M.; Li, J.; Fink, A.L. The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. J. Biol. Chem., 2003, 278, 40186-40197.
230. Hashimoto, M.; Takenouchi, T.; Rockenstein, E.; Masliah, E. Alpha-synuclein up-regulates expression of caveolin-1 and down-regulates extracellular signal-regulated kinase activity in B103 neuroblastoma cells: role in the pathogenesis of Parkinson's disease. J Neurochem., 2003, 85, 1468-1479.
231. Spencer, B.; Crews, L.; Masliah, E. Climbing the scaffolds of Parkinson's disease pathogenesis. Neuron, 2007, 53, 469-470.
232. Benarroch, E.E. Lipid rafts, protein scaffolds, and neurologic disease. Neurology, 2007, 69, 1635-1639.
233. Martinez, Z.; Zhu, M.; Han, S.; Fink, A.L. GMI specifically interacts with alpha-synuclein and inhibits fibrillation. Biochemistry, 2007, 46, 1868-1877.
234. Maguire-Zeiss, K.A.; Federoff, H.J. Convergent pathobiologic model of Parkinson's disease. Ann. NY Acad. Sci., 2003, 991, 152-166.
235. Li, J.; Zhu, M.; Manning-Bog, A.B.; Di Monte, D.A.; Fink, A.L. Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J., 2004, 18, 962-964.
236. Conway, K.A.; Rochet, J.C.; Bieganski, R.M.; Lansbury, P.T.; Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science, 2001, 294, 1346-1349.
237. Namba, Y.; Kawatsu, K.; Izumi, S.; Ueki, A.; Ikeda, K. Neumfibrillary tangles and senile plaques in brain of elderly leprosy patients. Lancet, 1992, 340, 978.
238. Chui, D.H.; Tabira, T.; Izumi, S.; Koya, G.; Ogata, J. Decreased beta-amyloid and increased abnormal Tau deposition in the brain of aged patients with leprosy. Am. J. Pathol., 1994, 145, 771-775.
239. Mcgeer, P.L.; Harada, N.; Kimura, H.; Mcgeer, E.G.; Schulzer, M. Prevalence of dementia amongst elderly japanese with leprosy - apparent effect of chronic drug-therapy. Dementia, 1992, 3, 146-149.
240. Tomiyama, T.; Shoji, A.; Kataoka, K.; Suwa, Y.; Asano, S.; Kaneko, H.; Endo, N. Inhibition of amyloid beta protein aggregation and neurritoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J. Biol. Chem., 1996, 271, 6839-6844.
241. Tomiyama, T.; Kaneko, H.; Kataoka, K.; Asano, S.; Endo, N. Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction. Biochem. J., 1997, 322 (Pt 3), 859-865.
242. Tomiyama, T.; Asano, S.; Suwa, Y.; Morita, T.; Kataoka, K.; Mori, H.; Endo, N. Rifampicin prevents the aggregation and neurotoxicity of amyloid beta protein in vitro. Biochem. Biophys. Res. Commun., 1994, 204, 76-83.
243. Li, J.; Zhu, M.; Rajamani, S.; Uversky, V.N.; Fink, A.L. Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chem. Biol., 2004, 11, 1513-1521.
244. Wu, J.A.; Attele, A.S.; Zhang, L.; Yuan, C.S. Anti-HIV activity of medicinal herbs: usage and potential development. Am. J. Chin. Med., 2001, 29, 69-81.
245. Ikezoe, T.; Chen, S.S.; Heber, D.; Taguchi, H.; Koeffler, H.P. Baicalin is a major component of PC-SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest. Prostate, 2001, 49, 285-292.
246. Gao, Z.; Huang, K.; Xu, H. Protective effects of flavonoids in the roots of Scutellaria baicalensis Georgi against hydrogen peroxide-induced oxidative stress in HS-SY5Y cells. Pharmacol. Res., 2001, 43, 173-178.
247. Shieh, D.E.; Liu, L.T.; Lin, C.C. Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonhi. Anticancer Res., 2000, 20, 2861-2865.
248. Zhu, M.; Rajamani, S.; Kaylor, J.; Han, S.; Zhou, F.; Fink, A.L. The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. J. Biol. Chem., 2004, 279, 26846-26857.
249. Hong, D.P.; Fink, A.L.; Uversky, V.N. Structural characteristics of alpha-synuclein oligomers stabilized by the flavonoid baicalein. J. Mol. Biol., 2008, 383, 214-223.
250. Hernan, M.A.; Takkouche, B.; Caamano-Isorna, F.; Gestal-Otero, J.J. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann. Neurol., 2002, 52, 276-284.
251. Litvan, I.; Halliday, G.; Hallett, M.; Goetz, C.G.; Rocca, W.; Duyckaerts, C.; Ben-Shlomo, Y.; Dickson, D.W.; Lang, A.E.; Chesselet, M.F.; Langston, W.J.; Di Monte, D.A.; Gasser, T.; Hagg, T.; Hardy, J.; Jenner, P.; Melamed, E.; Myers, R.H.; Parker, D.; Jr.; Price, D.L. The etiopathogenesis of Parkinson disease and suggestions for future research. Part 1. J. Neuropathol. Exp. Neurol., 2007, 66, 251-257.
252. Fratiglioni, L.; Wang, H.X. Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies. Behav. Brain Res, 2000, 113, 117-120.
253. Quik, M. Smoking, nicotine and Parkinson's disease. Trends Neurosci., 2004, 27, 561-568.
254. Hong, D.P.; Fink, A.L.; Uversky, V.N. Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation? Biochim. Biophys. Acta, 2009, 1794, 282-290.